NextCure agrees to merge with Avere Therapeutics in all-stock deal - NXTC News | RalliesNextCure agrees to merge with Avere Therapeutics in all-stock deal
N
NXTC• NextCure to merge with Avere Therapeutics
- NextCure agreed to merge with privately held Avere Therapeutics in an all-stock deal, with closing expected in 2H 2026.
- The combined company is expected to operate as Avere Therapeutics, trading on Nasdaq under ticker AVRX.
- Avere’s lead asset AVR-001 is a once-weekly oral IL-23 receptor antagonist in development for psoriasis, with Phase 1b data cited.
- A concurrent USD 320 million private placement includes USD 251 million of convertible notes to be exchanged for common stock at closing.
- Cash runway is expected to fund AVR-001 through a Phase 2b psoriasis readout, start of Phase 3 in psoriasis, start of Phase 2b in ulcerative colitis.
CRMT
•
